Literature DB >> 1419646

Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.

J M Bhatavdekar1, D D Patel, D D Giri, N H Karelia, H H Vora, N Ghosh, N G Shah, S N Trivedi, D B Balar.   

Abstract

Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419646      PMCID: PMC1977975          DOI: 10.1038/bjc.1992.395

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer.

Authors:  H J Staab; F A Anderer; E Stumpf; A Hornung; R Fischer; G Kieninger
Journal:  Am J Surg       Date:  1985-02       Impact factor: 2.565

2.  Follow-up of patients operated on for colorectal carcinoma.

Authors:  J Ovaska; H Järvinen; H Kujari; I Perttilä; J P Mecklin
Journal:  Am J Surg       Date:  1990-06       Impact factor: 2.565

3.  Carcinoembryonic antigen test for recurrent colorectal carcinoma. Inadequacy for early detection.

Authors:  C G Moertel; A J Schutt; V L Go
Journal:  JAMA       Date:  1978-03-13       Impact factor: 56.272

4.  Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.

Authors:  C Tondini; D F Hayes; R Gelman; I C Henderson; D W Kufe
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

5.  Determinants of survival in patients with unresectable colorectal liver metastases.

Authors:  A E Chang; S M Steinberg; M Culnane; D E White
Journal:  J Surg Oncol       Date:  1989-04       Impact factor: 3.454

6.  Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: a limitation in the use of serial CEA levels as an indicator for second-look surgery.

Authors:  R A Rittgers; G Steele; N Zamcheck; M S Loewenstein; P H Sugarbaker; R J Mayer; J J Lokich; J Maltz; R E Wilso
Journal:  J Natl Cancer Inst       Date:  1978-08       Impact factor: 13.506

7.  Value of plasma alpha-1-acid glycoprotein assay in the detection of human colorectal cancer: comparison with carcinoembryonic antigen.

Authors:  C Y Chu; L T Lai; H P Pokala
Journal:  J Natl Cancer Inst       Date:  1982-01       Impact factor: 13.506

8.  Plasma prolactin as an indicator of disease progression in advanced breast cancer.

Authors:  J M Bhatavdekar; N G Shah; D B Balar; D D Patel; A Bhaduri; S N Trivedi; N H Karelia; N Ghosh; M K Shukla; D D Giri
Journal:  Cancer       Date:  1990-05-01       Impact factor: 6.860

9.  The spread of rectal cancer and its effect on prognosis.

Authors:  C E DUKES; H J BUSSEY
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

10.  Tumor markers, liver function tests and symptoms in 115 patients with isolated colorectal liver metastases.

Authors:  M Lorenz; R P Baum; G Oremek; R Inglis; M Reimann-Kirkowa; G Hör; U Seiffert; C Hottenrott
Journal:  Int J Biol Markers       Date:  1989 Jan-Mar       Impact factor: 3.248

  10 in total
  9 in total

1.  Absence of prolactin gene expression in colorectal cancer.

Authors:  A J Wood; C M Thomas; K R Baumforth; J R Flavell; K W Scott; R H Grace; J G Williams; M R Holland; R Dunn; A G Jacobs; A Harrison; S Brun; N Plessis; P G Murray
Journal:  Mol Pathol       Date:  1999-06

2.  Tumor angiogenesis predicts recurrence with normal serum carcinoembryonic antigen in advanced rectal carcinoma patients.

Authors:  H Ishikawa; H Fujii; K Yamamoto; T Morita; M Hata; F Koyama; S Terauchi; S Sugimori; T Kobayashi; H Enomoto; S Yoshikawa; T Nishikawa; H Nakano
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Plasma and tumor prolactin in colorectal cancer patients.

Authors:  Y Ilan; O Sibirsky; N Livni; O Gofrit; V Barack; E Goldin
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

4.  Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner.

Authors:  Naveen K Neradugomma; Dharmalingam Subramaniam; Ossama W Tawfik; Vincent Goffin; T Rajendra Kumar; Roy A Jensen; Shrikant Anant
Journal:  Carcinogenesis       Date:  2013-11-21       Impact factor: 4.944

5.  Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.

Authors:  Atreyee Basu; Shashi Seth; Ashok K Chauhan; Nupur Bansal; Kanchan Arora; Anuradha Mahaur
Journal:  Ann Transl Med       Date:  2016-02

6.  Plasma prolactin in patients with colorectal cancer.

Authors:  Ahmad Reza Soroush; Hosein Mahmood Zadeh; Mehrnush Moemeni; Behnam Shakiba; Sara Elmi
Journal:  BMC Cancer       Date:  2004-12-23       Impact factor: 4.430

7.  A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes' stages A-D colorectal cancers.

Authors:  Sadia Mahboob; Seong Beom Ahn; Harish R Cheruku; David Cantor; Emma Rennel; Simon Fredriksson; Gabriella Edfeldt; Edmond J Breen; Alamgir Khan; Abidali Mohamedali; Md Golam Muktadir; Shoba Ranganathan; Sock-Hwee Tan; Edouard Nice; Mark S Baker
Journal:  Clin Proteomics       Date:  2015-04-08       Impact factor: 3.988

Review 8.  Hyperprolactinaemia.

Authors:  Irene Samperi; Kirstie Lithgow; Niki Karavitaki
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

Review 9.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.